Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study
Menée aux Etats-Unis dans un contexte de vie réelle auprès de patients atteints d'un lymphome à grandes cellules B réfractaire ou récidivant, cette étude multicentrique rétrospective évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité d'un traitement combinant tafasitamab et lénalidomide
Tafasitamab and lenalidomide yielded a considerably lower PFS and OS in DLBCL in the real-world setting compared to the L-MIND trial. Age over 70, ECOG performance status
≤
1, normal LDH, and relapse over 6 months from last treatment were associated with improved PFS. In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed/refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared to the L-MIND registration clinical trial for TL.
Blood 2023